Trials / Terminated
TerminatedNCT03871855
A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety of SHR-1702 monotherapy or in combination with Camrelizumab among advanced solid tumor subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1702 | Administered IV |
| DRUG | Camrelizumab | Administered IV |
Timeline
- Start date
- 2019-04-28
- Primary completion
- 2021-06-21
- Completion
- 2021-06-21
- First posted
- 2019-03-12
- Last updated
- 2023-06-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03871855. Inclusion in this directory is not an endorsement.